Dean urges wider health basket

Head of TA medical school says basket can be expanded without economic fallout.

May 21, 2006 22:55
1 minute read.
Dean urges wider health basket

pills 88. (photo credit: )


Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analysis from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief


Prof. Dov Lichtenberg, dean of Tel Aviv University's Sackler Faculty of Medicine, urged the government on Sunday to increase its expenditures on medications, saying that the basket of health services could be expanded significantly without causing undue problems for the economy. Speaking at a conference on-campus symposium on "Novel Strategies in Cancer Therapy" in honor of two physicians who shared the $1 million Dan David Foundation Prize for the Future Dimension, Lichtenberg said that although there had to be limits on health spending, the maximum was far from being reached. The two physicians who received the Dan David Prize (in addition to five who shared $2 million for the Past and Present Time Dimensions) were Prof. John Mendelsohn, president of the University of Texas MD Anderson Cancer Center in Houston, and Prof. Joseph Schlessinger of Yale University Medical School. Mendelsohn is the co-developer of Erbitux, one of the two colon cancer drugs that cost over NIS 20,000 per patient per month and are not covered by the health funds but which are being demanded by cancer patients holding a hunger strike, outside the Knesset since last week. Mendelsohn told The Jerusalem Post in an interview (the full interview will be published on Sunday's Health Page) that he was sorry his drug, a monoclonal antibody that has been proven to significantly extend the life of some colon cancer patients, was so expensive. "I have no control over that," said Mendelsohn. "The University of California at San Diego, where we did the development work, licensed the drug to a company that invested over $500 million in it, and they want a financial return. Costs of drug development are incredibly high, and the majority of experimental drugs get nowhere, so the company wants to recover the costs. It is tragic when patients who have cancer can't get the drug; this is true around the world, including the US where there are 40 or 50 million people without health insurance, in Israel, where there is national health insurance and even more in the developing world."

Join Jerusalem Post Premium Plus now for just $5 and upgrade your experience with an ads-free website and exclusive content. Click here>>

Related Content

Jisr az-Zarq
April 3, 2014
Residents of Jisr az-Zarqa beckon Israel Trail hikers to enjoy their town


Cookie Settings